Prognostic and predictive value of YKL-40 in stage IIB-III melanoma

This study investigates the prognostic and predictive value of YKL-40 in stage IIB–III melanoma patients who were randomized to adjuvant interferon &agr;-2b (IFN) or observation. Serum YKL-40 was determined postoperatively in patients from the Nordic IFN Trial (n=602), EORTC 18952 (n=246), and EORTC 18991 (n=386) (EORTC, European Organisation for Research and Treatment of Cancer). YKL-40 protein expression was determined in 300 tissue sections of primary melanoma or lymph node metastases from 204 Danish patients from the Nordic IFN Trial. Multivariate Cox analysis (including sex, age, stage, ulceration, YKL-40) showed that elevated baseline YKL-40 level was associated with shorter overall survival (OS) in observation groups from the Nordic IFN Trial and EORTC 18952 [hazard ratio (HR)=1.33; 95% confidence interval (CI) 1.01–1.74; P=0.04], but not in the interferon groups (1-year IFN: HR=0.97; 95% CI 0.76–1.25; P=0.83; 2-years IFN: HR=1.06; 95% CI 0.83–1.34; P=0.64). During follow-up, increases in YKL-40 were significantly associated with shorter OS, but not with recurrence-free survival in univariate analysis. YKL-40 expression was stronger in tumor-associated macrophages than melanoma cells in primary melanoma. High YKL-40 expression in macrophages in lymph node metastases was associated with shorter OS in the observation group (HR=2.76; 95% CI: 1.13–6.76, P=0.02), but not in the interferon-treated groups. YKL-40 was an independent prognostic biomarker of OS in melanoma patients stage IIB–III. High serum YKL-40 in poor-prognosis patients may originate from macrophages in the tumor microenvironment and the melanoma cells. Furthermore, we hypothesize that elevated serum YKL-40 after surgery may predict the efficacy of adjuvant IFN treatment.

[1]  Y. Modis,et al.  Chitinase 3-like 1 Regulates Cellular and Tissue Responses via IL-13 Receptor α2 , 2013, Cell reports.

[2]  R. Shao.  YKL-40 acts as an angiogenic factor to promote tumor angiogenesis , 2013, Front. Physiol..

[3]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[4]  D. Schadendorf,et al.  Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Larsen,et al.  YKL-40 Is Differentially Expressed in Human Embryonic Stem Cells and in Cell Progeny of the Three Germ Layers , 2012, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[6]  M. Weichenthal,et al.  Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. , 2012, European journal of cancer.

[7]  L. Deangelis,et al.  Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. , 2011, Neuro-oncology.

[8]  V. Lladó,et al.  Carbohydrate-binding motif in chitinase 3-like 1 (CHI3L1/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cells. , 2011, Clinical immunology.

[9]  B. Pedersen,et al.  IL-6, but not TNF-α, increases plasma YKL-40 in human subjects. , 2011, Cytokine.

[10]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[11]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[12]  S. Bojesen,et al.  Plasma YKL-40 levels in healthy subjects from the general population. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[13]  R. Shao,et al.  Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma* , 2011, The Journal of Biological Chemistry.

[14]  R. Shao,et al.  A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers , 2011, Molecular Cancer Therapeutics.

[15]  S. Aamdal,et al.  Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. , 2011, The Lancet. Oncology.

[16]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  N. Schultz,et al.  Plasma YKL-40: a potential new cancer biomarker? , 2009, Future oncology.

[18]  R. Flavell,et al.  Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13–induced tissue responses and apoptosis , 2009, The Journal of experimental medicine.

[19]  A. Fritsche,et al.  Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma , 2009, Melanoma research.

[20]  M. Weichenthal,et al.  Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse , 2009, Melanoma research.

[21]  S. Kjaer,et al.  YKL-40 tissue expression and plasma levels in patients with ovarian cancer , 2009, BMC Cancer.

[22]  E. Balslev,et al.  YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer , 2008, Breast Cancer Research and Treatment.

[23]  H. Nielsen,et al.  Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects , 2008, Cancer Epidemiology Biomarkers & Prevention.

[24]  A. Hauschild,et al.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.

[25]  A. Hauschild,et al.  EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. , 2008 .

[26]  I. Christensen,et al.  High serum levels of YKL‐40 in patients with squamous cell carcinoma of the head and neck are associated with short survival , 2008, International journal of cancer.

[27]  V. Castronovo,et al.  Experimental anti‐angiogenesis causes upregulation of genes associated with poor survival in glioblastoma , 2007, International journal of cancer.

[28]  E. Balslev,et al.  YKL-40 Expression in Benign and Malignant Lesions of the Breast: A Methodologic Study , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[29]  L. Larsen,et al.  YKL-40 Protein Expression in the Early Developing Human Musculoskeletal System , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[30]  E. Sauter,et al.  Increased expression of the inflammatory protein YKL‐40 in precancers of the breast , 2007, International journal of cancer.

[31]  E. Høgdall,et al.  YKL-40 protein expression in normal adult human tissues – an immunohistochemical study , 2007, Journal of Molecular Histology.

[32]  J. Gehl,et al.  Elevated serum level of YKL‐40 is an independent prognostic factor for poor survival in patients with metastatic melanoma , 2006, Cancer.

[33]  I. Christensen,et al.  Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Nielsen,et al.  Serum YKL-40, A New Prognostic Biomarker in Cancer Patients? , 2006, Cancer Epidemiology Biomarkers & Prevention.

[35]  A. Eggermont,et al.  Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial , 2005, The Lancet.

[36]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[37]  P. Kristjansen,et al.  Regulation of YKL‐40 expression during genotoxic or microenvironmental stress in human glioblastoma cells , 2005, Cancer science.

[38]  H. Nielsen,et al.  High serum YKL‐40 level after surgery for colorectal carcinoma is related to short survival , 2002, Cancer.

[39]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[40]  D. Schadendorf,et al.  Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. , 2012, European journal of cancer.

[41]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.